A new study brings into focus the relationship between diabetic GLP-1 users and the elevated risk of age-related eye disease.

NVO advances obesity pipeline with CagriSema and Amycretin while expanding through major deals amid rising competition.

I've been a Novo Nordisk bull for quite some time now, and I wouldn't be as spooked by the situation. Here's why. Novo Nordisk got a two-year-plus head start in the white-hot obesity drugs market, ...

The European Medicines Agency’s safety committee said on Friday Novo Nordisk’s popular weight-loss and diabetes drugs Wegovy ...

Later this month, the Street will have a fresh opportunity to gauge the potential for Amgen's experimental weight-loss drug, MariTide.

Today marks the first official agency warning about the possibility of these drugs—specifically Mounjaro—decreasing the ...

Eli Lilly and Camurus have entered into partnership worth up to $870m to develop long-acting therapies in cardiometabolic ...

Weight-loss drugs like Ozempic and Wegovy are used by more than 15 million adults in the U.S., or 4.5% of the population.